CS Tumor Size. We re on the Web! Visit us at www2.kumc.edu/kcr
|
|
- Erick Stanley
- 5 years ago
- Views:
Transcription
1 VOLUME 17 ISSUE 3 July 2013 We re on the Web! Visit us at www2.kumc.edu/kcr July is UV Awareness Month. It is that time of the year again for summer! This is a great opportunity to talk about skin cancer. Skin cancer is the most common of all cancers. Melanoma accounts for less than 5% of skin cancer cases. There are many ways to reduce your risk of skin cancer: Limit UV exposure Wear a hat Wear sunglasses Use sunscreen and lip balm of at least SPF 15 Stay in the shade as much as possible Check for abnormal moles and have them removed It is important to check your skin once a month for any unusual moles, freckles or other markings. The risk of getting melanoma is about 1 in 50 for Caucasians, 1 in 1,000 for African Ameircans, and 1 in 200 for Hispanics. CS Tumor Size For the Collaborative Stage Tumor Size for Melanoma this is the recoded size of the tumor in millimeters not the depth or thickness. Depth or thickness is recorded in Site Specific Factor 1 in the Measured Thickness, Breslow s Measurement table.
2 Why is text important? Provides the patient s cancer information in a readable format. Text information is readily available to defend coded items without going back to the source document. Documents unusual occurrences. Verifies edit checks. Central registry staff use text to verify coding discrepancies between facilities for the same patient. Provides information for: o recoding audits part of quality control at the central registry o researcher use confirm validity of data o facility use defend codes, document treatment from outside facilities o re-abstraction of historical data comparisons registrars can compare data by recoding the historical data to compare to more current data Examples of validating codes with text: Patient demographic codes: o Race code: 02 o Hispanic code: 0 o Sex code: 2 Text justification for patient demographic codes: B/F, non Hispanic Cancer ID and stage codes o Primary site: C341 o Histology: 8140 o Behavior: /3 o Grade: 2 o Tumor size: 020 o Laterality: 1 o Regional LNs positive: 00 o Regional LNs examined: 03 Text justification for Cancer ID and stage codes from pathology report 8/7/2007: Lobectomy of the right upper lobe lung reveals a moderately differentiated invasive adenocarcinoma measuring 2cm in greatest diameter. Three hilar lymph nodes are removed and are negative for carcinoma. Margins are negative. Abbreviated text justification for Cancer ID and stage codes 8/7/2007: Lobectomy RUL lung: mod diff inv adenoca. TS 2cm. 3 hilar LN removed, neg for ca. Margins neg.
3 Examples of Validating Codes with Text First course treatment information o Surgery primary site: 22 text justification Lumpectomy o Scope LNS surgery: 2 text justification SLN Bx o Chemotherapy: 87 text justification Refused o Radiation therapy: 7 - text justification Refused o Date hormone tx: 07/10/07 o Hormone therapy: 01 text justification Administered Follow-up and recurrence o Type last tumor follow-up: 01 text justification Readmit o Vital status: 1 text justification Alive o Recurrence type: 00 text justification None/disease-free NAACCR Approved Abbreviations Adenoca: Adenocarcinoma Ant: Anterior Bil: Bilateral Ca: Carcinoma Cont: Continue Dz: Disease Dx: Diagnosis Exc: Excision Lg Large Mets Metastatic, Metastases Rx Treatment Sx Symptoms Tx Treatment W/ With W/O Without W/U Workup NAACCR Approved At / Comparison < Less than, decrease = Equals > Greater than, increase - Negative + Positive X Times Reference:
4 What would be the correct surgical senario for this melanoma case? Patient presents s/p biopsy in Derm offce with melanoma 0.5mm,close to tissue edges. Our institution; Wide resection allowing for approx 1cm margins in all directions from the lesion; Path; residual melanoma insitu close to prior bx site. Our institution : re excision., Path- no residual melanoma Based on info provided it is 27, 30, 30. Patient came to our facility, excision of lesion on path read as "possible" solar lentigo in June. Consult at outside path lab read the specimen as melanoma in situ and was dated in August. What is the date of first contact AND the date of diagnosis? The date of first contact at your facility is the date the specimen was taken. It should be used to code the date of excision of lesion, date of diagnosis, and date of 1st contact. Pathology report states Wide excision with margins: Negative, Peripheral: at least 1.5cm & Deep: 0.8cm. Do both the Peripheral and Deep Margins need to be >1cm to qualify for codes 45-47? It is applicable to all margins. Is Evolving Melanoma reportable? The melanoma with behavior /2 and /3 is reportable. The term evolving does not automatically mean the behavior is borderline. I would recommend to clarify the behavior with pathologist. I have a case with the following listed in the final path of the shave biopsy: malignant melanoma, at least 1.15mm in thickness with deeper perifollicular nests at a depth of 1.36mm, a microsatellite focus at a depth of 1.7mm and a nest deeper in the dermis adjacent to an involved eccrine duct at a depth of 2.3mm. Anatomic level IV. margins are positive. Patient then goes on to have an excision and that final path shows: malignant melanoma, superficial spreading type, invasive to a depth of 1.01mm, anatomic level IV. Margins are negative. What would the correct depth be to code in SSF1? In this case, code the depth from the final pathology report of the Excision procedure of 1.01mm as 101. Patient has melanoma of scalp and a few months after resection has in transit mets in scalp near the skin graft. What is the best code for 'type of recurrence'? Most likely it is local, but if the mets originate in the scar, then it can be coded trocar. Do you have any questions that you would like answered in an upcoming newsletter? your question(s) to: vhundley@kumc.edu
5 Reporting Schedule Month of Diagnosis Due to KCR by: January 2013 July 2013 February 2013 August 2013 March 2013 September 2013 April 2013 October 2013 May 2013 November 2013 June 2013 December 2013 July 2013 January 2014 August 2013 February 2014 September 2013 March 2014 October 2013 April 2014 November 2013 May 2014 December 2013 June 2014 Are You Current? Use NAACCR Record Layout Version 12.2 for transmitting 2012 cases and NAACCR Version 12.2 Edits for error checking. NAACCR Record Layout Version 13 and NAACCR Version 13 Edits have been released and are effective for cases diagnosed in We have converted the KCR database to v13 and can accept v13 and prior files. Due to the limited number of changes between v13 and v12.2, cases diagnosed in 2013 may be abstracted and transmitted to KCR using v12.2 standards if necessary. Please contact your registry software vendor when you are ready to convert to v13. KCR will distribute updated Abstract Plus software later this summer. Use Collaborative Staging & Coding Manual, Version (released December 2011) ( to code collaborative stage fields for 2012 and 2013 cases. Use the 2012 Hematopoietic & Lymphoid Database and Manual for 2012 and 2013 cases. The 2012 database is available as a web-based version at or as a software download at The web-based version is the preferred method to access the current data. Both versions include the Multiple Primaries Calculator and the current Hematopoietic Coding Manual. Please pay close attention to pages for new histology terms and codes. Please check our website to download the Kansas Cancer Registry Coding and Information Manual, ( Use Multiple Primary and Histology Coding Rules Manual (Revised September 27, 2011) ( for all cases diagnosed January 1, 2007 and forward.
6 ICD-9-CM Codes Case Finding List 2013 Explanation of ICD-9CM Code 140._ _, Malignant neoplasms, stated or presumed to be primary (of specified sites), and certain 174._ , 209.7_ specified histologies (Except ) Benign neoplasms of brain and spinal cord neoplasm 227.3, Benign neoplasm of pituitary gland, craniopharyngeal duct (pouch) and pineal gland Hemangioma; of intracranial structures Lymphangioma, any site Note: Includes only lymphangioma of the brain, other parts of nervous system and endocrine gland Carcinoma in situ (Except and 233.1) , 237.6, Neoplasm of uncertain behavior of endocrine glands and nervous system: pituitary gland, craniopharyngeal duct and pineal gland Neoplasm of uncertain behavior of endocrine glands and nervous system: brain and spinal cord, meninges, endocrine glands and other and unspecified parts of nervous system Polycythemia vera (9950/3) Plasma cells 238.7_ 239.6, Other lymphatic and hematopoietic diseases Neoplasms of unspecified nature, brain, endocrine glands and other parts of nervous system Macroglobulinemia (Waldenström's macroglobulinemia) Other specified disorders of metabolism Reportable includes terms: Hand-Schuller-Christian disease; histiocytosis (acute) (chronic); histiocytosis X (chronic) Hemophagocytic syndrome (histiocytic syndromes) Familial polycythemia (syndrome for polycythemia vera) 795.0_ _ 796.7_ Papanicolaou smear of cervix and vagina with cytologic evidence of malignancy Abnormal cytologic smear of anus and anal HPV V10.0_ - V10.9_ Personal history of malignancy Note: Screen for recurrences, subsequent primaries, and/or subsequent treatment V12.41 Personal history of benign neoplasm of the brain V58.0, V58.1_ V67.1, V67.2 V76._ V86._ Encounter for radiotherapy, chemotherapy, immunotherapy Follow up examination: following radiotherapy or chemotherapy Special screening for malignant neoplasm Estrogen receptor positive status [ER+], negative status (ER-)
7 Updating Contact Information! Please visit our website (www2.kumc.edu/kcr/downloads) Submit the updated form to Victoria Hundley ( Fax: ) The Kansas Cancer Registry (KCR), under the direction of Dr. Sue Min Lai, has expanded in recent years to collect and maintain a population based longitudinal database of all Kansans diagnosed with cancer. KCR is the only population-based source of information on cancer incidence in the State of Kansas. It provides information on the occurrence of cancer, stage at diagnosis, survival and subpopulations affected by different types of cancer. Registry information can be used by researchers to evaluate the effectiveness of new treatments and by public health professionals to implement and monitor prevention efforts. Thanks to facilities across the state of Kansas who report cancer cases, KCR has quality data to help in the fight against cancer. KCR Staff Sue-Min Lai SLAI@kumc.edu John Keighley JKEIGHLE@kumc.edu Sarma Garimella SGARIMEL@kumc.edu Christi Baron CBARON@kumc.edu Qin Wang QWANG@kumc.edu Jessica Jungk JJUNGK@kumc.edu Victoria Hundley VHUNDLEY@kumc.edu Thanks to all KCR staff members who contributed to the publication of this newsletter. Kansas Cancer Registry University of Kansas Medical Center 130 Support Services, MS Rainbow Boulevard, Kansas City, Kansas Tel: Fax:
We re on the Web! Visit us at www2.kumc.edu/kcr
VOLUME 18 ISSUE 2 April 2014 We re on the Web! Visit us at www2.kumc.edu/kcr April 7-11 is National Cancer Registrars Week! This week was established as an annual celebration to acknowledge the central
More informationWe re on the Web! Visit us at VOLUME 19 ISSUE 1. January 2015
VOLUME 19 ISSUE 1 January 2015 We re on the Web! Visit us at www.kumc.edu/kcr January is National Cervical Cancer Screening Month. Cervical cancer begins in the lining of the cervix (organ connecting the
More informationWe re on the Web! Visit us at
VOLUME 20 ISSUE 2 April 2016 We re on the Web! Visit us at www.kumc.edu/kcr April 11-15 is National Cancer Registrars Week! This week was established as an annual celebration to acknowledge the central
More informationWe re on the Web! Visit us at
VOLUME 21 ISSUE 2 April 2017 We re on the Web! Visit us at www.kumc.edu/kcr April 10-14 is National Cancer Registrars Week! This week was established as an annual celebration to acknowledge the central
More informationAPPENDIX I. Free-Standing Radiation Therapy Centers Cancer Case Identification Program
APPENDIX I Free-Standing Radiation Therapy Centers Cancer Case Identification Program I-1 Sending Radiation Therapy data to FCDS Beginning January 1, 2003, all Florida Radiation Therapy Centers must send
More informationWho What When Where Why. Case Finding 5 W s. NAACCR Webinar Series. Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC
Who What When Where Why Case Finding 5 W s NAACCR 2010-2011 Webinar Series Presented by: Joyce L. Jones, CTR Professional Registry Services, LLC Agenda Case Finding Purpose Reportable lists Benign intracranial
More informationREPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after
REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after The following lists are intended to assist you, as the reporter, in identifying the reportable neoplasms for your facility. Any reportable
More informationCalifornia Cancer Registry Production Automation and Quality Control Unit Data Alert - Registrar
Production Automation and Quality Control Unit Data Alert - Registrar 2015-061 REVISED Casefinding List FY2016 Please see additions and revisions noted below in red text. ICD-10-CM Codes have been adopted
More informationComprehensive ICD-10-CM Casefinding Code List for Reportable Tumors for 2018 (Effective Dates: 10/1/2017-9/30/2018)
Comprehensive ICD-10-CM Casefinding Code List for Reportable Tumors for 2018 (Effective Dates: 10/1/2017-9/30/2018) Please refer to your standard setter(s) for specific reporting requirements before using
More informationCANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume
More informationI.2 CNExT This section was software specific and deleted in 2008.
CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I Changes and Clarifications 8th th Edition Revised May 2008 SECTION
More information4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines
SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific
More information2017 ICD-10-CM Casefinding List (Abbreviated listing from SEER website) COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors
2017 ICD-10-CM Casefinding List (Abbreviated listing from SEER website) COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors ICD-10 Code Explanation of Code Malignant neoplasms (excluding
More informationCASEFINDING. KCR Abstractor s Training
CASEFINDING KCR Abstractor s Training 1 Introduction Casefinding Definition Purpose Methods Sources vs Resources Reportable Cancer Conditions Non-Reportable Conditions Ambiguous Terminology 2 https://www.google.com/search?q=puzzle+pieces&client=firefox-a&hs=mdc&rls=org.mozilla
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationCalifornia Cancer Registry Production Automation and Quality Control Unit Data Alert - Registrar
Production Automation and Quality Control Unit Data Alert - Registrar 2015-063 REVISED - Clarification Casefinding List for FY2016 Updated Please see additional codes inadvertently excluded from the previous
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More informationREPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2017 and after
REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2017 and after The following lists are intended to assist you, as the reporter, in identifying the reportable neoplasms for your facility. Any reportable
More informationRequirements for Abstracted Text
Slide 1 Requirements for Abstracted Text Principles of Abstracting Lesson 3: Purpose of Text Slide 2 Available Text Fields Place of Diagnosis Immunotherapy Chemotherapy Hormone Therapy Other Therapy Radiation
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More information2010 Cancer Data Collection Updates: Standards Volume II, Introduction. What s New for 2010
2010 Cancer Data Collection Updates: Standards Volume II, Version 12 NAACCR 2009 2010 Webinar Series Introduction What s New for 2010 Record length and record layout New/changed data items Multiple Primary
More informationKyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System
Kyle L. Ziegler, CTR California Cancer Registry U.C. Davis Health System Overview New Data Items Reportability Clarifications New Coding Rules Grade ICD-O-3 Changes Collaborative Stage v0205 2 New Data
More informationCollaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]
CS Tumor Size Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the physician's
More informationCODING PRIMARY SITE. Nadya Dimitrova
CODING PRIMARY SITE Nadya Dimitrova OUTLINE What is coding and why do we need it? ICD-10 and ICD-O ICD-O-3 Topography coding rules ICD-O-3 online WHAT IS CODING AND WHY DO WE NEED IT? Coding: to assign
More informationACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:
More informationEVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013
EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013 Head and Neck Coding and Staging Head and Neck Coding and Staging Anatomy & Primary Site Sequencing and MPH
More informationFINALIZED SEER SINQ QUESTIONS April July, 2017
20170040 Source 1: 2016 SEER Manual pgs: 91 Source 2: 2007 MP/H Rules Notes: Lung MP/H Rules/Histology--Lung: What is the histology code for lung cancer case identified pathologically from a metastatic
More informationMCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR
MCR: MANAGEMENT OF 2018 CHANGES By: Maricarmen Traverso-Ortiz MPH, CGG, CTR LEARNING OBJECTIVES Discuss a summary of the new changes for 2018 Overview of how the Maryland Cancer Registry is managing and
More informationChapter 2 Neoplasms C00-D49 November 11, Chapter 2: Neoplasms Category: C00-D49 Official Coding Guidelines: Section 1.C.2, p.
Chapter 2: Neoplasms Category: C00-D49 Official Coding Guidelines: Section 1.C.2, p. 22 1 C00 C75 Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, hematopoietic
More informationOutline. How to Use the AJCC Cancer Staging Manual, 7 th ed. 7/9/2015 FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015.
1 How to Use the AJCC Cancer Staging Manual, 7 th ed. FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015 Steven Peace, CTR Outline 2 History, Purpose and Background Purchase and Ordering Information
More information1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) =
Follow-up, Data Quality and Utilization Lesson 8 Page 5: Correcting the Edits Report Instructions: Use the spaces provided to fix the edit by providing the valid value for the incorrect data item. This
More informationFormat Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te
Florida Cancer Data System International Classification of Diseases for Oncology ICD-O-3 1 Basic Concepts Primary Site/Topography Histology/Morphology Behavior Grade/Immunophenotype 2 ICD-O 3 Structure/Format
More informationQ: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done.
Q&A Breast Webinar Q: One of my investigators is interested in knowing when Oncotype DX data collection was implemented. That data is collected in SSFs 22 and 23. I remember that the SSFs for breast were
More informationFCDS TENTATIVE V11 TO V11.1 IMPLEMENTATION SCHEDULE
NAACCR V11.1 UPDATES ZIP CODE, FIPS COUNTY, FLORIDA CITY NAME VERIFICATION FILE (COMMA SEPARATED TEXT FILE) CANCER TRAINING: PRINCIPLES AND PRACTICE OF CANCER REGISTRATION, SURVEILLANCE AND CONTROL, JULY
More informationNCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions
NCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without
More informationThursday, August 16, :30 AM - 4:30 PM and Friday, August 17, :30 AM 12:00 PM Crowne Plaza 830 Phillips Lane Louisville, KY 40209
KCR newsletter March 2018 KCR 2018 Fall Workshop/Regional Meeting 2018 Tri-State Regional Cancer Registrars Meeting Presented by: Kentucky Cancer Registry, Indiana Cancer Consortium, and Ohio Cancer Incidence
More informationEvaluation of Abstracting: Cancers Diagnosed in MCSS Quality Control Report 2005:2. Elaine N. Collins, M.A., R.H.I.A., C.T.R
Evaluation of Abstracting: Cancers Diagnosed in 2001 MCSS Quality Control Report 2005:2 Elaine N. Collins, M.A., R.H.I.A., C.T.R Jane E. Braun, M.S., C.T.R John Soler, M.P.H September 2005 Minnesota Department
More information2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.
Slide 1 2007 New Data Items Data Due in: Days In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules. Slide 2 5 New Data Items Ambiguous Terminology
More informationDonna M. Hansen, CTR Auditor & Training Coordinator California Cancer Registry
Donna M. Hansen, CTR Auditor & Training Coordinator California Cancer Registry April 2015 2015 Data Changes New Data Items Revised Data Items ICD-0-3 Reportability Change New ICDO Terms and Codes SEER
More informationCancer as a Disease. Linda D. Rego, CTR March 2009
Cancer as a Disease Linda D. Rego, CTR March 2009 Historic perspective First records date as early as 2500 B.C. In Egypt recorded on papyrus Outlines pharmacological, mechanical and magical treatments
More informationOSCaR UPDATE. Manager s Update Donald Shipley, MS. Oregon State Cancer Registry
Oregon State Cancer Registry OSCaR UPDATE VOLUME 8, QUARTER 4 W INTER 2008 Manager s Update Donald Shipley, MS Since the Fall issue of OSCaR Update, the registry staff has completed several significant
More informationMONTHLY JOURNAL OF UPDATES AND INFORMATION. Revised November 2008 (Additions and revisions appear in bold)
OCTOBER/ NOVEMBER 2008 MONTHLY JOURNAL OF UPDATES AND INFORMATION FCDS CASEFINDING LIST FOR REPORTABLE TUMORS Revised November 2008 (Additions and revisions appear in bold) Casefinding List (Revised November
More informationCommission on Cancer Updates
Commission on Cancer Updates OBJECTIVES PROVIDE CANCER REGISTRARS WITH INFORMATION ABOUT CURRENT COC 2018 CHANGES DISCUSS CHANGES RELATED TO CANCER REGISTRY DATA COLLECTION DISCUSS CHANGES RELATED TO CANCER
More informationFINALIZED SEER SINQ S MAY 2012
FINALIZED SEER SINQ S MAY 2012 : 20120039 Primary site/heme & Lymphoid Neoplasms: What site do I code this to and what rule applies? How did you arrive at this? Please advise. See discussion. Patient with
More informationNAACCR Webinar Series 1
NAACCR 2009 2010 Webinar Series Collecting Cancer Data: Kidney 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes 3 NAACCR 2009 2010 Webinar
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationObtaining the diagnosis:
CANCER SURGERY Obtaining the diagnosis: Most cancers are first biopsied in order to determine tumor type. Incisional biopsies extract small portions of tumor for microscopic examination. Excisional biopsies
More informationCase Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
More informationWHI Extension Appendix A, Form Report of Cancer Outcome (Ver. 8.2) Page 1
WHI Extension Appendix A, Form 130 - Report of Cancer Outcome (Ver. 8.2) Page 1 FORM: 130 - REPORT OF CANCER OUTCOME Version: 8.2 October 30, 2008 Description: When used: Purpose: 4-page form filled out
More informationQUICK-START GUIDE NCDB Participant Use File (NCDB PUF)
QUICK-START GUIDE 2015 NCDB Participant Use File (NCDB PUF) The data included in this zipped file are provided in a flat text file format, and should be read with software such as SAS, SPSS (PASW), STATA,
More informationPlease complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE
Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES PHYSICAL EXAMINATION CASE 1: FEMALE REPRODUCTIVE 3/5 Patient presents through the emergency room with
More informationInformational Abstracts: A Guide to Quality Abstracting
Informational Abstracts: A Guide to Quality Abstracting Presented by NCRA Education Committee Carole Eberle, BS, CTR Louise Schuman, MA, CTR NCRA Education Committee NCRA Strategic Planning and Education
More informationNeoplasms/Lymphoma/Leukemia
Neoplasms/Lymphoma/Leukemia Session Guidelines This is a 15 minute webinar session for CNC physicians and staff CNC holds webinars monthly to address topics related to risk adjustment documentation and
More informationBACK TO TABLE OF CONTENTS FOCUS ON MELANOMA Oncology Annual Report BAPTIST HEALTH LEXINGTON ONCOLOGY ANNUAL REPORT
FOCUS ON MELANOMA 2014 Oncology Annual Report BAPTIST HEALTH LEXINGTON 1 2014 ONCOLOGY ANNUAL REPORT TABLE OF CONTENTS What is melanoma?...3 Who is at risk for melanoma?...3 What causes melanoma?...4 What
More information7/29/ Grade Coding Instructions ICD-O-3 Updates. Outline. Introduction to Coding Grade for 2014+
2014 Grade Coding Instructions ICD-O-3 Updates 1 I M P L E M E N T A T I O N T I M E L I N E ( S ) 2 0 1 4 F C D S D A M A P P E N D I X H A N D O U T S F C D S A N N U A L C O N F E R E N C E O R L A
More informationInstructions for Coding Grade for 2014+
Instructions for Coding for 2014+ GRADE, DIFFERENTIATION OR CELL INDICATOR Item Length: 1 NAACCR Item #: 440 NAACCR Name:, Differentiation for solid tumors (Codes 1, 2, 3, 4, 9) and Cell Indicator for
More informationAJCC TNM STAGING UPDATES ARE YOU READY FOR TNM?
AJCC TNM STAGING UPDATES ARE YOU READY FOR TNM? FCRA Annual Conference Boca Raton, Florida 7/26/2016 Steven Peace, CTR 1 Introduction Order AJCC Cancer Staging Manual, 7 th ed. How To Use - AJCC Cancer
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More information2018 New Grade Coding Rules It s a Good Thing!
2018 New Grade Coding Rules It s a Good Thing! Presented by Donna M. Hansen, CTR California Cancer Registry NAACCR Webinar May 1, 2018 & May 2, 2018 1 Acknowledgement Special Thanks To: Jennifer Ruhl,
More informationICD-10-CM - Session 2. Cardiovascular Conditions, Neoplasms and Diabetes
ICD-10-CM - Session 2 Cardiovascular Conditions, Neoplasms and Diabetes Agenda General coding guidelines Acute myocardial infarction Hypertension Cerebrovascular accidents and sequelae Neoplasm and history
More informationSkin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1
Skin Cancer AMERICAN OSTEOPATHIC COLLEGE OF OCCUPATIONAL & PREVENTIVE MEDICINE OMED 2012 October 8, 2012 E. Robert Wanat II, D.O., M.P.H. Learning Objectives: Identify the 3 Basic Types of Skin Cancer
More informationSetting the stage for change: upgrading the physician cancer case reporting application in New York
Setting the stage for change: upgrading the physician cancer case reporting application in New York April Austin New York State Cancer Registry (NYSCR) July 12, 2018 June 13, 2018 Aerial view of Thousand
More informationCS Tumor Size CS Extension CS Tumor Size/Ext Eval CS Lymph Nodes CS Lymph Nodes Eval Reg LN Pos Reg LN Exam CS Mets at DX CS Mets Eval
C70.0, C71.0-C71.9 C70.0 Cerebral meninges C71.0 Cerebrum C71.1 Frontal lobe C71.2 Temporal lobe C71.3 Parietal lobe C71.4 Occipital lobe C71.5 Ventricle, NOS C71.6 Cerebellum, NOS C71.7 Brain stem C71.8
More informationFCDS Text and Documentation Requirements: A Key Component to Providing High Quality Data
FCDS Text and Documentation Requirements: A Key Component to Providing High Quality Data 2011 FCDS Educational Webcast Series Mayra Espino, BA, RHIT, CTR Steven Peace, BS, CTR August 18, 2011 CDC-NPCR
More informationDecember 2002 Monthly Memo
FLORIDA CANCER DATA SYSTEM December 2002 Monthly Memo CODING COMPLEX MORPHOLOGIC DIAGNOSES CODING COMPLEX BREAST HISTOLOGIES Apply these guidelines in priority order. Use the first guideline that applies
More informationNAACR Treatment Webinar Quiz 1
NAACR Treatment Webinar Quiz 1 1. Which of the following would NOT be considered cancer-directed treatment? a. Hemicolectomy b. Incisional biopsy c. Whole breast radiation d. MRI e. All of the above f.
More informationCollaborative Staging Manual and Coding Instructions Part II: Primary Site Schema
C44.0-C44.9, C51.0-C51.2, C51.8-C51.9, C60.0-C60.2, C60.8-C60.9, C63.2 (M-8720-8790) C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of ear and unspecified parts of face C44.4 Skin of
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationICD-O CODING Third Edition
Slide 1 ICD-O CODING Third Edition PART I An introduction to the ICD-O-3 Coding Manual This is part 1 of a 2-part slide presentation. Use the navigation buttons below this panel to advance the slides.
More informationInteractive Staging Bee
Interactive Staging Bee ROBIN BILLET, MA, CTR GA/SC REGIONAL CONFERENCE NOVEMBER 6, 2018? Clinical Staging includes any information obtained about the extent of cancer obtained before initiation of treatment
More informationTake Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules
Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules Case 1 72 year old white female presents with a nodular thyroid. This was biopsied in
More informationSEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING
SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING OVERVIEW What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets Site Specific Data Items (SSDI) SEER Summary
More informationL ARYNX S TAGING F ORM
CLI N I CA L Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX T0 Tis a b L ARYNX S TAGING F ORM LATERALITY: TUMOR SIZE: left
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationDirectly Coded Summary Stage Melanoma
Directly Coded Summary Stage Melanoma National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control, National Program of Cancer Registries Directly Coded
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationCANCER PROGRAM Annual Report. Cancer Registry Database 2008 CANCER CASES AND BREAST CANCER SITE OUTCOMES ANALYSIS
CANCER PROGRAM 2009 Annual Report Cancer Registry Database 2008 CANCER CASES AND BREAST CANCER SITE OUTCOMES ANALYSIS 1 2008 Annual Report - Site Table Site Total Class Sex AJCC TNM Collaborative Stage
More informationPart VIII Entering Information Into the Urology Report Form
North Carolina Central Cancer Registry Instructions and Reporting Requirements Module 8 Electronic Reporting For Urology Physician Practices May 2013 North Carolina Central Cancer Registry State Center
More informationData Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data,
Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data, 2004-2012 Jeanne Whitlock, MSLS, CTR Julie George, MS Ron Shore, MPH Fawn D. Vigneau, JD, MPH Metropolitan
More informationThis section allows identifying the facility, this information is important for data quality follow up. Source of Standard. Source of Standard
Data Dictionary Case Administration This section allows identifying the facility, this information is important for data quality follow up Facility Name This identifier is needed to evaluate This data
More informationVISUAL EDITING GUIDELINES March 2015 (revised June 2015)
March 2015 (revised June 2015) Developed for The Cancer Registry of Greater California under the direction of Winny Roshala, BA, CTR, Data Quality Control Director By the following contributing Authors:
More informationNAACCR WEBINAR: ABSTRACTING THYROID/LARYNX CANCER INCIDENCE FLORIDA: PEDIATRIC CANCER ADMISSIONS (TOTAL), ANALYTIC CASES ONLY FCDS REGISTER VOL.
NAACCR WEBINAR: ABSTRACTING THYROID/LARYNX CANCER INCIDENCE AND TREATMENT DATA ON 3/6/2008. SESSION #5 OF 8 IS BEING HELD AT BOCA RATON COMMUNITY HOSPITAL, MOFFITT CANCER CENTER, AND SHANDS UNIVERSITY
More informationDATA REQUEST RESPONSE- XRT AND BRACHYTHERAPY
Date: 10 th April 2018 DATA REQUEST RESPONSE- XRT AND BRACHYTHERAPY Request: 1. Utilization Data of Overseas Beam Therapy and Brachytherapy 2. Diagnoses Data of Overseas Claims for Beam Therapy and Brachytherapy
More informationCase Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.
Case Scenario 1 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of
More informationSeventh Edition Staging 2017 Breast
Seventh Edition Staging 2017 Breast Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written
More informationClassification of Neoplasms
Classification of Neoplasms ICD-10 Chapter 2, Neoplasms Codes C00-D48 Notes at beginning of Chapter 2 Classified by behaviour and site Correct use of Alphabetic index required Main terms Modifiers Table
More informationFINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma
Case Scenario 1 HNP: A 70 year old white male presents with dysphagia. The patient is a current smoker, current user of alcohol and is HPV positive. A CT of the Neck showed mass in the left pyriform sinus.
More informationExercise 15: CSv2 Data Item Coding Instructions ANSWERS
Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report
More informationDATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #
DATA STANDARDS AND QUALITY CONTROL MEMORANDUM DSQC #2006-01 CATEGORY: CLARIFICATION SUBJECT: RESCINDMENT - DSQC MEMORANDUM 2002-08 Coding Complex Morphologic Diagnoses (revised 8/02) EFFECTIVE: For Cases
More informationBenign/Borderline Brain and ONS Tumors in the NAACCR Data
Benign/Borderline Brain and ONS Tumors in the NAACCR Data DURC Data Assessment Work Group Bin Huang 2011 NAACCR Conference 6/23/2011 Authors Louisiana Tumor Registry Patricia Andrews, MPH Meichin Hsieh,
More informationSite Specific Coding Rules Benign and Borderline Intracranial and CNS Tumors
Multiple Primary and Histology Site Specific Coding Rules Benign and Borderline Intracranial and CNS Tumors 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are
More informationCoding Pitfalls 9/11/14
Coding Pitfalls 2013 2014 NAACCR Webinar Series September 11, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationCase Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.
Case Scenario 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of alcohol.
More informationSKIN CANCER. Most common cancer diagnosis 40% of all cancers
SKIN CANCER Most common cancer diagnosis 40% of all cancers OBJECTIVES Review common and uncommon cancers of the skin. Special emphasis on melanoma and dysplastic nevus Review pathology/tnm/staging, which
More informationGreater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute
2008 ANNUAL REPORT Greater Baltimore Medical Center Sandra & Malcolm Berman Cancer Institute Cancer Registry Report The Cancer Data Management System/ Cancer Registry collects data on all types of cancer
More informationSeventh Edition Staging 2017 Melanoma. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.
Seventh Edition Staging 2017 Melanoma Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written
More informationCancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
More informationYou Want ME to Stage that Case???
You Want ME to Stage that Case??? Jayne Holubowsky, CTR, Director, Virginia Cancer Registry 2 nd DelMarVa-DC Regional Conference October 11, 2018 What s New in the AJCC 8 th Edition Objectives Explain
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Skin Malignancies 2/4/2010 NAACCR 2009 2010 Webinar Series Questions Please use the Q&A panel to submit your questions Send questions to All Panelist Collecting Cancer Data: Skin
More information